Review the scope of FDA authority of drug promotion and advertising. Define “label” and “labeling” and “false and “misleading”. Gain insight on FDA’s social media guidance, use of off-label information, and considerations for other government and state entities. Review the role of a corporate compliance program in managing the risks of marketing a drug.
Heidi Gertner, Partner, Hogan LovellsUS LLP
This session was recorded as part of FDLI’s Virtual Introduction to Drug Law and Regulation Course in April 2021.